{"entity":{"id":"tilt-123","kind":"drug","name":"TILT-123","aka":["Ad5/3-E2F-d24-hTNFa-IRES-hIL2 (TILT-123)"],"tldr":"TILT-123 is an oncolytic virus from TILT Biotherapeutics Ltd., in registered phase 2 trials for ovarian cancer.","summary":"TILT-123 is listed on ClinicalTrials.gov as an intervention in 1 registered phase 2 trial sponsored by TILT Biotherapeutics Ltd., in ovarian cancer. An oncolytic virus, as described in the registry record: a virus engineered to infect and burst tumour cells and alert the immune system. OnCo records the agent from the registry alone; approvals, results and the sponsor's own description will follow as they are published.","status":"phase-2","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov: trials of TILT-123","url":"https://clinicaltrials.gov/search?intr=TILT-123"}],"tags":["pipeline","ctgov-ingest","registry-only"],"related":[],"cancers":["ovarian"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct05271318"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2, registry-only)","editedOn":"2026-09-16"},"code":"TILT-123","modality":"Oncolytic virus","mechanism":"An oncolytic virus, as described in the registry record: a virus engineered to infect and burst tumour cells and alert the immune system.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/tilt-123/","neighbours":{"cancer":[{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"}],"trial":[{"id":"nct05271318","kind":"trial","name":"Oncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab (Phase 1a) and Pegylated Liposomal Doxorubicin (Phase 1b) ","route":"/trials/nct05271318/"}]}}